Company profile
Goldenwell Biotech, Inc.
OTC: GWLL · Healthcare · Medical - Pharmaceuticals
#1165 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
16DFH 11DQ 18GM 19SS 27
v0.1 · 65/100 weight · provisional
↑ market scale, growth stability · ↓ operating margin, net margin
Methodology →Revenue TTM
$23.2k
Rev growth YoY (TTM)
-37.9%
Net income (FY)
-$296.5k
Employees
3
as of 2026-08-19
Market cap
$76.2M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$55$552025
Net income-$296.5k-$296.5k2025
Operating income-$113.3k-$113.3k2025
Total assets$36.1k$36.1k2025
Liabilities$379.8k$379.8k2025
Equity-$343.7k-$343.7k2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY21
FY21
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Goldenwell Biotech, Inc.’s revenue?
Goldenwell Biotech, Inc. booked $55 in FY2025 revenue, contracting 60% year over year — slower than 85% of Healthcare companies we track, at a -539038.2% net margin.
Peers · Healthcare
Itonis, Inc.25DGlobeStar Therapeutics Corporation——VMS Rehab Systems, Inc.——Revolution Medicines, Inc.52DSummit Therapeutics Inc.49DSpyre Therapeutics, Inc.64CNeighbors
Summit →Key facts
CEOShuang Liu
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersHudson, OH
ExchangeOTC: GWLL
Employees3
IPO date2022-09-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.